Behavioral Interventions - A.G (Onno) Holleboom, MD, PhD slidesets

Innovations in NAFLD Care Workshop 2023

Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia

European Meeting on HIV & Hepatitis 2018

Pro Standpoint- Nancy Reau, MD

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

HIV Vaccines - Where Are We? - Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD

Global HIV Clinical Forum 2020

Resistance to INSTI's - Charles Boucher, MD, PhD

WHO Guidelines and Policies of testing | Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD

International Viral Hepatitis Elimination Meeting (IVHEM) 2016

101 Biomarker in Fibrotic Liver Disease OR the Armamentarium of Non-invasive Test to Stage Liver Disease - Jörn Schattenberg, MD slidesets

Innovations in NAFLD Care Workshop 2023

Impact of Sars-Cov-2 Omicron and Delta Sub-Lineage AY.4.2 Variant on Neutralization by Sera of Patients Treated With Different Licensed Monoclonal Antibodies

European Meeting on HIV & Hepatitis 2022

Has treating HBV reduced liver cancer incidence? - Jinlin Hou, MD

Asian Conference on Hepatitis and AIDS (ACHA) 2014

Considerations in Switching to Newer Regimens in Patients Suppressed on Older Drugs - Gary Rubin, MD, MCFP, AAHIVS

European HIV Clinical Forum 2022